NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Mestag Therapeutics

Mestag Therapeutics

Private
CambridgeHealthcare & Life Scienceshttps://www.mestagtherapeutics.com/

Last Round

VC Round

Mar 17, 2026

Total Funding Raised

$46.9M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Mestag Therapeutics is a biotechnology company that develops first-in-class immunotherapies targeting fibroblast-immune interactions to treat cancer and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverycancer immunotherapyfibroblast immunologytargeted LTBR agonistLTBRclinical trialstumor microenvironmentbiotech startupantibody therapeuticsbiopharmaoncologyinflammatory diseasedrug developmentclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mestag Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Mestag Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Mestag Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 17, 2026
GrantAug 28, 2024
SeedAug 3, 2021

Key People

Founding team and executive leadership

Susan Hill

Chief Executive Officer, Co-Founder & Board Member

Founding Team

Pascal Merchiers

Chief Development Officer (CDO)

Executive Team

Mestag Therapeutics Investors

Notable investors and investment history

Mestag Therapeutics investors
InvestorRounds
Forbion Capital PartnersVC Round
SV Health InvestorsVC Round, Seed
GVVC Round, Seed
ForbionVC Round, Seed
Northpond VenturesVC Round, Seed
Johnson & Johnson Innovation - JJDCVC Round
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 17, 2026

    $40M raised in early funding.

Mestag Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mestag Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mestag Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range45
Year Founded2020
Last FundingMar 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.